Literature DB >> 32647009

Direct relationship between increased expression and mistrafficking of the Charcot-Marie-Tooth-associated protein PMP22.

Justin T Marinko1,2, Bruce D Carter1,3, Charles R Sanders4,2,5.   

Abstract

Charcot-Marie-Tooth disease (CMT) is a neuropathy of the peripheral nervous system that afflicts ∼1:2500 people. The most common form of this disease (CMT1A, 1:4000) is associated with duplication of chromosome fragment 17p11.2-12, which results in a third WT PMP22 allele. In rodent models overexpressing the PMP22 (peripheral myelin protein 22) protein and in dermal fibroblasts from patients with CMT1A, PMP22 aggregates have been observed. This suggests that overexpression of PMP22 under CMT1A conditions overwhelms the endoplasmic reticulum quality control system, leading to formation of cytotoxic aggregates. In this work, we used a single-cell flow-cytometry trafficking assay to quantitatively examine the relationship between PMP22 expression and trafficking efficiency in individual cells. We observed that as expression of WT or disease variants of PMP22 is increased, the amount of intracellular PMP22 increases to a greater extent than the amount of surface-trafficked protein. This was true for both transiently transfected cells and PMP22 stable expressing cells. Our results support the notion that overexpression of PMP22 in CMT1A leads to a disproportionate increase in misfolding and mistrafficking of PMP22, which is likely a contributor to disease pathology and progression.
© 2020 Marinko et al.

Entities:  

Keywords:  Charcot–Marie–Tooth disease (CMT); cell surface protein; flow cytometry; membrane protein; membrane trafficking; myelin; peripheral neuropathy; protein folding; protein misfolding

Mesh:

Substances:

Year:  2020        PMID: 32647009      PMCID: PMC7443497          DOI: 10.1074/jbc.AC120.014940

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Isolation of transcriptionally regulated sequences associated with neuronal and non-neuronal cell interactions.

Authors:  A A Welcher; M De Leon; U Suter; G J Snipes; S O Meakin; E M Shooter
Journal:  Prog Brain Res       Date:  1992       Impact factor: 2.453

2.  The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones.

Authors:  Jenny Fortun; Jonathan D Verrier; Jocelyn C Go; Irina Madorsky; William A Dunn; Lucia Notterpek
Journal:  Neurobiol Dis       Date:  2006-12-13       Impact factor: 5.996

3.  PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts.

Authors:  Sooyeon Lee; Stephanie Amici; Hagai Tavori; Waylon M Zeng; Steven Freeland; Sergio Fazio; Lucia Notterpek
Journal:  J Neurosci       Date:  2014-11-26       Impact factor: 6.167

Review 4.  The peripheral myelin protein 22 and epithelial membrane protein family.

Authors:  A M Jetten; U Suter
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2000

Review 5.  Charcot-Marie-Tooth disease: an overview of genotypes, phenotypes, and clinical management strategies.

Authors:  Rima El-Abassi; John D England; Gregory T Carter
Journal:  PM R       Date:  2014-01-13       Impact factor: 2.298

6.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

7.  Reversible folding of human peripheral myelin protein 22, a tetraspan membrane protein.

Authors:  Jonathan P Schlebach; Dungeng Peng; Brett M Kroncke; Kathleen F Mittendorf; Malathi Narayan; Bruce D Carter; Charles R Sanders
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

8.  The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy.

Authors:  Christina DiVincenzo; Christopher D Elzinga; Adam C Medeiros; Izabela Karbassi; Jeremiah R Jones; Matthew C Evans; Corey D Braastad; Crystal M Bishop; Malgorzata Jaremko; Zhenyuan Wang; Khalida Liaquat; Carol A Hoffman; Michelle D York; Sat D Batish; James R Lupski; Joseph J Higgins
Journal:  Mol Genet Genomic Med       Date:  2014-08-21       Impact factor: 2.183

9.  Caveats in the Established Understanding of CMT1A.

Authors:  Jun Li
Journal:  Ann Clin Transl Neurol       Date:  2017-06-15       Impact factor: 4.511

10.  Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.

Authors:  Sooyeon Lee; Hannah Bazick; Vinita Chittoor-Vinod; Mohammed Omar Al Salihi; Guangbin Xia; Lucia Notterpek
Journal:  Am J Pathol       Date:  2017-12-12       Impact factor: 4.307

View more
  4 in total

1.  Ion mobility-mass spectrometry reveals the role of peripheral myelin protein dimers in peripheral neuropathy.

Authors:  Sarah M Fantin; Kristine F Parson; Pramod Yadav; Brock Juliano; Geoffrey C Li; Charles R Sanders; Melanie D Ohi; Brandon T Ruotolo
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

2.  Glycosylation Limits Forward Trafficking of the Tetraspan Membrane Protein PMP22.

Authors:  Justin T Marinko; Madison T Wright; Jonathan P Schlebach; Katherine R Clowes; Darren R Heintzman; Lars Plate; Charles R Sanders
Journal:  J Biol Chem       Date:  2021-04-29       Impact factor: 5.157

Review 3.  Membrane proteins enter the fold.

Authors:  Dagan C Marx; Karen G Fleming
Journal:  Curr Opin Struct Biol       Date:  2021-05-08       Impact factor: 7.786

4.  Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice.

Authors:  Michael E Shy; Maurizio D'Antonio; Yunhong Bai; Caroline Treins; Vera G Volpi; Cristina Scapin; Cinzia Ferri; Rosa Mastrangelo; Thierry Touvier; Francesca Florio; Francesca Bianchi; Ubaldo Del Carro; Frank F Baas; David Wang; Pierre Miniou; Philippe Guedat
Journal:  Mol Neurobiol       Date:  2022-04-30       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.